Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 10938

Edit search filters
  1. A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

    La Crosse, WI

  2. Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes (REVITALIZE 1)

    Scottsdale/Phoenix, AZ

  3. Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates (COLT)

    Rochester, MN

  4. A Phase 1B/​2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (RECOVER-VITAL)

    Rochester, MN

  6. Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM (Protocol AM)

    Scottsdale/Phoenix, AZ

  7. Tradipitant After GLP-1R Agonist In Healthy, Overweight, or Class I or II Obese Volunteers

    Rochester, MN

  8. A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

    Rochester, MN

  9. Cara CDRM (Conduction Disturbance Risk Monitor) 2.0

    Rochester, MN

  10. Breastmilk in Response to a Bout of Exercise

    Rochester, MN

.

Mayo Clinic Footer